Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 4
Submit an article Journal homepage
339
Views
20
CrossRef citations to date
0
Altmetric
Review

Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences

Bernice Tsoi Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada. [email protected]; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada. [email protected]; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
,
Lisa Masucci Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada
,
Kaitryn Campbell Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
,
Michael Drummond Centre for Health Economics, University of York, Heslington, York, UK; Centre for Health Economics, University of York, Heslington, York, UK
,
Daria O’Reilly Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
&
Ron Goeree Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Pages 497-511 | Published online: 09 Jan 2014

References

  • Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat. Rev. Drug Discov. 9(4), 277–291 (2010).
  • Henshall C, Mardhani-Bayne L, Frønsdal KB, Klemp M. Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities. Int. J. Technol. Assess. Health Care 27(3), 253–260 (2011).
  • Villeneuve PJ. The placebo standard in regulatory market approval: why the Declaration of Helsinki has been ignored for 35 years. McGill J. Med. 6, 52–55 (2001).
  • Stewart A, Aubrey P, Belsey J. Addressing the health technology assessment of biosimilar pharmaceuticals. Curr. Med. Res. Opin. 26(9), 2119–2126 (2010).
  • van Nooten F, Holmstrom S, Green J, Wiklund I, Odeyemi IA, Wilcox TK. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov. Today 17(11-12), 615–622 (2012).
  • Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10(7), 495–506 (2011).
  • ICH harmonised tripartite guideline: choice of control group and related issues in clinical trials (E10). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, Switzerland (2000).
  • Garrido MV, Kristensen FB, Nielsen CP, Busse R. Health Technology Assessment and Health Policy Making- Current Status, Challenges and Potential. World Health Organization, on behalf the European Observatory on Health Systems and Policies, Copenhagen (2008).
  • Sorenson C, Drummond M, Kanavos P. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union. World Health Organization, on behalf of the European Observatory on Health Systems and Policies, Geneva (2008).
  • Centre for Innovation in Regulatory Science. Evidentiary Requirements in Clinical Development: Synchronising Phase III Requirements to Meet Multiple Needs. (Workshop synopsis). The Centre, Geneva, Switzerland (2011).
  • Barker R. A flexible blueprint for the future of drug development. Lancet 375(9712), 357–359 (2010).
  • Liberti LE, Pichler F, Walker SR. Preparing for regulator review and reimbursement decisions- a case for cooperation between regulatory authorities, sponsors and health technology assessment agencies. Pharm. Med. 23(5–6), 263–267 (2009).
  • Lehner J-P, Epstein RS, Salimi T. Integrating new approaches for clinical development: translational research and relative effectiveness. J. Comp. Eff. Res. 1(1 Suppl. 1), 15–21 (2012).
  • Martin M, Lensberg B, Drummond M, McGuire A. Relative efficacy- towards a new frontier? ISPOR Connections 17(5), 8–10 (2011).
  • Berger ML, Grainger D. Comparative effectiveness research: the view from a pharmaceutical company. Pharmacoeconomics 28(10), 915–922 (2010).
  • Frønsdal K, Pichler F, Mardhani-Bayne L et al. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry. Int. J. Technol. Assess. Health Care 28(4), 374–381 (2012).
  • European Medicines Agency. Road Map to 2015: The European Medicines Agency’s Contribution to Science, Medicines and Health. European Medicines Agency, London, United Kingdom (2010).
  • European Medicines Agency. European Medicines Agency and EUnetHTA Joint Action start collaboration on European Public Assessment Report (EPAR) Contribution to Relative Effectiveness Assessments [press release]. European Medicines Agency, London, United Kingdom (2010).
  • Luria X. Regulatory Science Workforce Needs to Maintain a Robust Global Therapeutics Pipeline [Presentation]. Institute of Medicine Workshop, Washington, DC (2011).
  • Moseley GB 3rd. The prospects for medical technology in the next decade. Stud. Health Technol. Inform. 118, 15–31 (2005).
  • Institute for Regulatory Science. Regulation and Reimbursement: Two Sides of the Same Coin? The Institute, Alexandria, VA (2008).
  • Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health 14(4), 608–615 (2011).
  • Tapestry Networks. Pilots of Multi-Country, Multi-Stakeholder Consultations in Drug Development: Promoting Clarity on Sources of Medicinal Value. Tapestry Networks, Waltham, MA (2011).
  • Leader M. Calling for six standards to value innovation in healthcare. J. BioLaw Bus. 11(1), 49–51 (2008).
  • Keja J. HTA moves center stage. AccessPoint IMS Health Econ. Outcomes Res. 1(2), 15–17 (2011).
  • Tapestry Networks. Pilots of Multi-Country, Multi-Stakeholder Consultations in Drug Development: From Proof of Concept to Tangible Benefits: From Proof of Concept to Tangible Benefits. Tapestry Networks, Waltham, MA (2012).
  • Tapestry Networks. Alzheimer’s Disease Working Group: Advancing Progress in the face of Dynamic Science and Constrained Resources. Tapestry Networks, Waltham, MA (2012).
  • Tapestry Networks. Improving Health Outcomes in Type 2 Diabetes: Putting a Shared Value Framework into Practice. Tapestry Networks, Waltham, MA (2010).
  • Australian Government Department of Health and Ageing. Memorandum of understanding with medicines Australia. (2010).
  • Canadian Agency for Drugs and Technologies in Health. CDR Update. The Agency, Ottawa (2012).
  • Association bilateral meeting – BIOTECanada - Meeting Minutes – 2009-11-18. Health Canada, Ottawa (2009).
  • Canadian Agency for Drugs and Technologies in Health. CDR Update. The Agency, Ottawa (2009).
  • Department of Health and Human Services. Memorandum of understanding between United States Food and Drug Administration and the Centers for Medicare and Medicaid Services. Fed. Regist. 75, 48699–48700 (2010).
  • MaRSEXCITE. Application Guide. MaRSEXCITE, Toronto (2012).
  • PriceWaterhouseCoopers. Pharma 2020: Which Path will you Take? PriceWater house Coopers, Hamilton, ON (2012).
  • Woosley RL, Rice G. A new system for moving drugs to market. Issues Sci. Technol. 21(2), 63–68 (2005).
  • Eichler HG, Oye K, Baird LG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91(3), 426–437 (2012).
  • Eichler HG. Adaptive Licensing: A Useful Approach for Drug Licensing in the EU [Presentation]. European Medicines Agency, London, UK (2012).
  • NEWDIGS (New Drug Development Paradigms). Catalyzing the Transformation of Healthcare Innovation. MIT Center for Biomedical Innovation, Cambridge, MA (2010).
  • Institute of Medicine. Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development: Workshop Summary. The National Academies Press, Washington, DC (2012).
  • Health Canada. The Progressive Licensing Framework: Concept Paper for Discussion. Health Canada, Ottawa (2007).
  • Health Canada. Progressive Licensing Project. Health Canada, Ottawa (2012).
  • Usdin S. Progressive Thinking for FDA. BioCentury Publications, Inc, San Carlos, CA (2011).
  • Guyatt G, Rennie D, Meade MO, Cook DJ. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. McGraw Hill Medical, New York (2008).
  • Canadian Agency for Drugs and Technologies in Health. CDR Update. The Agency, Ottawa (2008).
  • Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs–same or different? Value Health 12(4), 402–404 (2009).
  • Trueman P, Hurry M, Bending M, Hutton J. The feasibility of harmonizing health technology assessments across jurisdictions: a case study of drug eluting stents. Int. J. Technol. Assess. Health Care 25(4), 455–462 (2009).
  • Tolley K. Pharmaceutical market access and the challenges of health technology assessment in the United Kingdom. Drug Dev. Res. 71(8), 478–484 (2010).
  • European Medicines Agency. Implementing the European Medicines Agency’s Road map to 2015: the Agency’s contribution to Science, Medicines, Health. European Medicines Agency, London, UK (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.